Compare FTAI Aviation Ltd (FTAI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Recursion Pharmaceuticals Inc — how do they compare? FTAI Aviation Ltd trades at $169.51 (market cap $17.57B), while Recursion Pharmaceuticals Inc trades at $4.24 (market cap $2.14B). The key difference: FTAI Aviation Ltd is far larger — about 8.2× Recursion Pharmaceuticals Inc's market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FTAI | RXRX | |
|---|---|---|
Market Cap | $17.57B | $2.14B |
Volume | 1,905,014 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $310.04 | $6.79 |
52-Week Low | $152.80 | $2.84 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $20.69B | $1.66B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.47, down 3.07% today, with a bearish technical signal from moving averages. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS expectations. Recent developments include a $500M share buyback program and a strategic acquisition of 27 Boeing aircraft, signaling growth focus. Analyst consensus remains unanimously bullish with a $321.25 price target, highlighting institutional confidence despite near-term earnings volatility.
The outlook for FTAI is positive based on robust analyst support and strategic expansions, but risks include consecutive EPS misses and a high P/E ratio of 37.35. Investors face volatility from operational cash flow challenges and competitive pressures in the aviation sector, though the buyback and new partnerships provide catalysts for recovery.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
